Natural Matrix Product Assessment via Cell-Based Network Assays
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods are inadequate for assessing the therapeutic or beneficial effects of products comprising natural matrices, which operate through complex network interactions rather than traditional pharmacological mechanisms, leading to regulatory challenges and inefficiencies in demonstrating compliance with medical device regulations.
Innovation Solution
A method involving cell-based assays to evaluate the regulation of biological activity networks and functional resilience across different batches of natural matrix products, determining if they modify a pathological or altered physiological state through a physiological mechanism of action.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional pharmacological assessment methods are used for natural matrix products, then the assessment process is simple and familiar, but the methods are inadequate for capturing complex network interactions and physiological mechanisms
Solution Approach 1:
The assessment method is segmented into multiple distinct phases: in vitro cell-based assays to evaluate individual biological activities, in vivo animal studies to assess network-level effects, and data integration steps to correlate findings across scales. This segmentation allows comprehensive capture of complex interactions while maintaining systematic organization of the assessment process.
Solution Approach 2:
The assessment framework is designed to be universally applicable to different natural matrix products by evaluating multiple biological activities simultaneously through cell-based assays. The method can accommodate various product types and mechanisms of action, making it a multi-functional tool that addresses diverse assessment needs within a unified approach.
2Measurement precision
If cell-based assays and network regulation analysis are implemented to accurately assess physiological mechanisms, then the assessment precision improves, but the time and resources required increase
Solution Approach 1:
In vitro cell-based assays are conducted as preliminary screening steps before proceeding to more time-consuming in vivo animal studies. This preliminary action identifies products showing promising network-regulating effects, allowing early elimination of unsuitable candidates and reducing overall assessment time by avoiding unnecessary animal studies for products that clearly fail initial screening.
Solution Approach 2:
The assessment methodology incorporates iterative feedback loops where in vitro results inform the design and interpretation of in vivo studies, and vice versa. This feedback mechanism allows refinement of hypotheses and focused investigation of specific biological activities, reducing time loss by avoiding redundant or irrelevant experimental steps.
3Reliability
If comprehensive network regulation analysis is performed across multiple biological activities, then the therapeutic validation becomes more reliable, but the manufacturing and operational complexity increases
Solution Approach 1:
Bioinformatics tools and computational algorithms serve as intermediaries that automatically integrate and analyze data from multiple biological activity assays. These intermediary systems process complex datasets, identify network-level patterns, and generate standardized reports, reducing the operational burden on researchers while maintaining comprehensive analysis of multiple biological activities.
4Stability of the object's composition
If the method evaluates functional resilience across different batches, then product consistency and regulatory compliance improve, but the quantity of testing required increases
Solution Approach 1:
The methodology evaluates functional resilience by measuring changes in key biological activity parameters across different batches rather than requiring complete compositional analysis. By focusing on critical functional parameters that indicate network-regulating effects, the method ensures batch consistency with reduced material requirements compared to comprehensive compositional testing of each batch.
Data Source
AI summary
The present invention relates to new methods enabling the evolution of the medical arts passing from the use of artificial substances that are chemically or biologically defined to self-assembling natural entities, obtained from natural raw materials with industrial processes that preserve the endogenous properties thereof, thereby preserving their capability to interact with the networks of the living kingdom (including humans); wherein said natural entities cannot be defined with the classical quali-quantitative composition schemes. The invention therefore provides new methods for determining when a therapeutic or beneficial product exerts its therapeutic or beneficial effect through a physiological mode of action. This method provides a necessary tool for the skilled person to assess the mechanism of action of a therapeutic or beneficial product which, with the new developments in the regulatory framework for medical devices and food supplements has become a relevant feature to assess and for which no methods are available in the art.